Antimicrobial Resistance Diagnostics Market Size Worth USD 5.25 Billion by 2034 | CAGR: 4.7%
The market size is expected to reach USD 5.25 billion by 2034, according to a new study by Polaris Market Research. The report “Antimicrobial Resistance Diagnostics Market Size, Share, Trends, & Industry Analysis Report By Technology, By Pathogen, By Specimen and Workflow, By End Use, and By Region; Market Forecast, 2026–2034” offers a detailed analysis of current market dynamics, segment performance, and growth prospects through the forecast period.
Valued at USD 3.46 billion in 2025, the market is expected to register a CAGR of 4.7% from 2026 to 2034. Clinicians are under pressure to confirm resistance before empirical antibiotics have run their course, which is steering laboratory investment toward faster, more targeted testing.
Suppliers are widening their menus rather than replacing established methods. Culture-based susceptibility testing remains the benchmark in most laboratories, and faster phenotypic systems and molecular panels are being layered on top of it for time-critical cases such as bloodstream infections. Growth through 2034 will depend on how quickly suppliers can turn faster results into workflows that laboratories can validate and afford.
Questions? Request a sample or make an inquiry before buying this report by clicking the link below: Antimicrobial Resistance Diagnostics Market Report
Public-health programs are adding to the momentum. The DxAMR Collaborative was launched in Accra, Ghana, in June 2025 by the Fleming Initiative, GARDP and FIND to promote innovation, access and implementation of diagnostics, particularly in low- and middle-income countries. The World Health Organization’s 2024 Antimicrobial Resistance Diagnostic Initiative policy brief also highlighted the need to strengthen laboratory capacity and improve access to quality diagnostic testing. Together, these initiatives underline the public-health case for resistance detection, although turning that case into test purchases will depend on funding and the availability of validated products.
Antimicrobial Resistance Diagnostics Market Report Highlights
- Conventional Culture and AST led the technology segment in 2025, as laboratories continue to treat measured susceptibility results as the reference point against which newer methods are validated.
- PCR and syndromic panels are projected to grow at a CAGR of 5.76% during the forecast period, as multiplex formats let a single run report both the organism and the resistance markers it carries.
- Resistant Enterobacterales was the largest pathogen segment in 2025, as resistant Gram-negative bacteria are among the most common causes of the urinary tract and bloodstream infections that laboratories are asked to resolve.
- Direct-from-clinical-sample testing is gaining ground, as bypassing culture isolation can bring resistance results forward to the point where antibiotic choices are first reviewed.
- Hospital laboratories remained the largest end-use segment in 2025, as inpatient care concentrates the high-risk, high-volume cases where a resistance result changes the next prescribing decision.
- Outpatient and point-of-care settings are an emerging opportunity, as compact, rapid formats aim to return resistance results while the patient is still being seen.
- North America held the largest regional share of 37.10% in 2025, supported by a dense network of hospital laboratories and a concentration of leading diagnostics manufacturers.
- Asia Pacific is projected to grow at a CAGR of 5.86% from 2026 to 2034, as national AMR action plans and expanding laboratory networks widen access to resistance testing.
- Key players in the market include bioMérieux SA, Bruker Corporation, Danaher Corporation, Molsid SAS, PhAST Corp., Q-linea AB, QIAGEN N.V., F. Hoffmann-La Roche Ltd (Roche Diagnostics), Seegene Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., and Waters Corporation.
Antimicrobial Resistance Diagnostics Market report on the technology, pathogen, specimen and workflow, end use, and region:
By Technology Outlook (Revenue, USD Billion, 2021–2034)
- Conventional Culture and AST
- Rapid Phenotypic AST
- PCR and Syndromic Panels
- Sequencing Based
- Mass Spectrometry Based
- Immunoassay and Others
By Pathogen Outlook (Revenue, USD Billion, 2021–2034)
- Resistant Enterobacterales
- Resistant Non Fermenters
- MRSA and Other Resistant Gram Positives
- Drug Resistant Neisseria gonorrhoeae
- Drug Resistant Tuberculosis
- Others
By Specimen and Workflow Outlook (Revenue, USD Billion, 2021–2034)
- Positive Blood Culture
- Direct From Clinical Sample
- Isolate Based
By End Use Outlook (Revenue, USD Billion, 2021–2034)
- Hospital Laboratories
- Reference and Diagnostic Laboratories
- Outpatient and Point of Care Settings
- Public Health and Research Institutions
By Regional Outlook (Revenue, USD Billion, 2021–2034)
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Taiwan
- Australia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
